Fudan-Zhangjiang released its 2026 interim report, with net profit attributable to the parent company at 36.895 million yuan, up 545.57% from the same period last year. Total operating revenue was 372 million yuan, down 4.58% year on year. Net cash inflow from operating activities was 82.6267 million yuan, up 32.81% year on year, marking three consecutive years of growth. The company's latest asset-liability ratio was 10.79%, gross margin was 91.63%, return on equity was 1.71%, and diluted earnings per share was 0.04 yuan.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co LtdNet profit surged 545.57% year on year, though revenue declined slightly.
